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Perinatal
Human immunodeficiency virus (HIV) is a condition that
increasingly affects women, especially women of childbear-
ing age. Early in the HIV epidemic, HIV infection and AIDS
were diagnosed in relatively few women in the United States.
Today, the HIV/AIDS epidemic represents a growing and
persistent health threat to women, especially young women
and women of color. In 2001 and 2002, HIV infection was
the leading cause of death for African American women aged
25–34 years and was among the four leading causes of death
for African American women aged 20–24 and 35–44 years,
as well as Hispanic women aged 35–44 years [1, 2].
Although HIV is increasing among women, the incidence
in children from perinatal transmission is decreasing. With
recommendations for routine screening for HIV during preg-
nancy and the availability of effective interventions to dra-
matically reduce the risk of perinatal transmission, the num-
ber of annual perinatally acquired AIDS cases from 1985–
1994 has declined approximately 95% [3], representing one
of the most striking success stories in the 25-year effort to
reduce the impact of HIV/AIDS in the United States.
HIV infection can be transmitted from mother to child in
utero, during labor and delivery and through breastfeeding.
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In the absence of intervention and without breastfeeding,
the risk of perinatal HIV transmission is approximately 25%
(range 13–39%) [4]. Evidence suggests that in the absence
of breastfeeding, 30% of transmission occurs before birth
and 70% around the time of delivery [4].
In February 1994, the results of the Pediatric AIDS
Clinical Trials Group (PACTG) Protocol 076 documented
that zidovudine (ZDV) chemoprophylaxis, initiated at 14–
34 weeks gestation and continued through pregnancy, fol-
lowed by intravenous ZDV during labor and oral ZDV to
the infant for the first 6 weeks of life, could reduce peri-
natal HIV transmission by nearly 70% [5]. A U. S. Public
Health Service (USPHS) task force subsequently issued rec-
ommendations for the use of ZDV for reduction of perinatal
HIV transmission [6] and universal prenatal HIV counseling
and HIV testing with consent for all pregnant women in the
United States [7]. Epidemiologic data have further confirmed
the efficacy of ZDV for reduction of perinatal transmission,
even among women with advanced disease, low CD4+ T-
lymphocyte counts, and prior ZDV therapy [8–13]. In ad-
dition, substantial advances have taken place in the treat-
ment and monitoring of persons with HIV disease, which
have resulted in changes in standard antiretroviral therapy
for HIV infected adults. More aggressive combination drug
regimens are now recommended to maximally suppress vi-
ral replication. For pregnant women, however, the benefits
of antiretroviral therapy must be weighed against the risk
of adverse events to the woman, fetus, and newborn; how-
ever pregnancy is generally not a reason to defer standard
therapy. It should be offered with the addition of ZDV for
prevention of perinatal HIV transmission to HIV infected
pregnant women [4, 14].
For women with HIV infection, preconception care must
focus on recommendations for safe sexual practices that pre-
vent HIV transmission to sexual partners and protect women
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from acquiring potentially harmful sexually transmitted
diseases or even additional strains of HIV that may be more
virulent or resistant to therapy. Women also need education
about perinatal transmission risks and prevention strategies,
expectations for the child’s future, and where desired, ef-
fective contraception until the optimal maternal health sta-
tus for pregnancy is achieved, including appropriate ther-
apy to maximally reduce viral load and optimize immune
function. For HIV-infected women desiring pregnancy, spe-
cific counseling regarding available reproductive options that
both prevent HIV exposure to uninfected partners, as well
as preventing superinfection with resistant or more virulent
virus should be discussed. The USPHS recommends that the
following be included in preconception counseling for HIV-
infected women: 1) selection of effective and appropriate
contraceptive methods to reduce the likelihood of unintended
pregnancy; 2) education and counseling about perinatal
transmission risks, strategies to reduce those risks, and po-
tential effects of HIV or treatment on pregnancy course and
outcomes; 3) initiation or modification of antiretroviral ther-
apy avoiding agents with potential toxicity for the devel-
oping fetus (e.g., efavirenz, hydroxyurea), choosing agents
effective in reducing perinatal HIV transmission, attaining
a stable, maximally suppressed maternal viral load, evaluat-
ing and controlling for therapy associated side effects which
may adversely impact maternal-fetal health outcomes (e.g.,
hyperglycemia, anemia, hepatic toxicity); 4) evaluation and
appropriate prophylaxis for opportunistic infections and ad-
ministration of immunizations (e.g., influenza, pneumococ-
cal, or hepatitis B vaccines) as indicated; 5) optimization of
maternal nutritional status; 6) institution of the standard mea-
sures for preconception evaluation and management (e.g., as-
sessment of reproductive and familial genetic history, screen-
ing for infectious diseases/sexually transmitted diseases, and
initiation of folic acid supplementation); 7) screening for ma-
ternal psychological and substance abuse disorders, and 8)
planning for perinatal consultation if desired or indicated [4].
The USPHS further notes that HIV infected women of child-
bearing potential receive primary healthcare services in var-
ious clinical settings, e.g., family planning, family medicine,
internal medicine, obstetrics/gynecology, and stress that pri-
mary health-care providers should consider the fundamental
principles of preconception counseling an integral compo-
nent of comprehensive primary health care for improving
maternal and child health outcomes [4].
The Infectious Disease Society of America (IDSA) rec-
ommends in-depth discussions about childbearing early in
the course of HIV care for women who express a desire for a
future pregnancy, who are not trying to conceive but are not
using appropriate contraception consistently or who express
uncertainty about reproductive plans. The goal of these dis-
cussions is to ensure informed decisions about contraception
and to offer preconception counseling if pregnancy is desired.
IDSA recommends that providers regularly assess women’s
reproductive plans and their desire to have questions an-
swered and, that providers question patients at each visit
about interval menstrual history and sexual and contracep-
tive practices, offering pregnancy testing as indicated [15].
The American College of Obstetricians and Gynecolo-
gists (ACOG) and the American Academy of Pediatrics
(AAP) recommend that screening for HIV infection be
strongly recommended for women with unknown HIV status
and who are considering pregnancy [16, 17]. The Centers for
Disease Control and Prevention (CDC) is considering this
recommendation for its revised recommendations for HIV
testing in healthcare settings planned for 2006 [3]. In addi-
tion, these organizations as well as the Institute of Medicine
and the U. S. Preventive Services Task Force recommend
universal prenatal screening for HIV infection [3, 17–21], so
that HIV-infected pregnant women can take full advantage of
the available interventions to reduce perinatal transmission
as well as to receive care for themselves. These organiza-
tions support an opt-out approach to HIV screening, (i.e.,
patients are notified that HIV testing will be done and con-
sent is inferred unless testing is declined) [3] to normalize
HIV testing in health care settings and to reduce the barriers
clinicians experience with specific HIV test counseling and
written informed consent.
Pre-test discussions regarding risk reduction for HIV in-
fection are not a requirement for HIV testing and can be
provided in the context of discussions of reproductive health
and STD prevention. Routine HIV testing during preconcep-
tion care can be integrated with other aspects of preconcep-
tion care that require a blood sample and should not require
substantial additional time commitments by providers. Im-
proved implementation of preconception care will further
extend the success in reducing perinatal HIV transmission
in the U. S. as well as improve access to HIV testing and
care to women. Because the issues accompanying HIV treat-
ment during pregnancy and perinatal prophylaxis are rather
complex, the case for preconception counseling and care for
known HIV-infected women is clear.
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